- Home
- FEBO vs SABS Comparison
FEBO vs SABS Comparison
Compare FEBO & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEBO
- SABS
- Stock Information
- Founded
- FEBO 1993
- SABS 2014
- Country
- FEBO Hong Kong
- SABS United States
- Employees
- FEBO N/A
- SABS N/A
- Industry
- FEBO
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- FEBO
- SABS Health Care
- Exchange
- FEBO Nasdaq
- SABS Nasdaq
- Market Cap
- FEBO 12.7M
- SABS 11.4M
- IPO Year
- FEBO 2023
- SABS N/A
- Fundamental
- Price
- FEBO $1.22
- SABS $1.50
- Analyst Decision
- FEBO
- SABS Strong Buy
- Analyst Count
- FEBO 0
- SABS 5
- Target Price
- FEBO N/A
- SABS $11.40
- AVG Volume (30 Days)
- FEBO 11.8K
- SABS 25.0K
- Earning Date
- FEBO 05-02-2025
- SABS 05-19-2025
- Dividend Yield
- FEBO N/A
- SABS N/A
- EPS Growth
- FEBO N/A
- SABS N/A
- EPS
- FEBO N/A
- SABS N/A
- Revenue
- FEBO $16,319,897.00
- SABS $1,322,410.00
- Revenue This Year
- FEBO N/A
- SABS N/A
- Revenue Next Year
- FEBO N/A
- SABS $50.00
- P/E Ratio
- FEBO N/A
- SABS N/A
- Revenue Growth
- FEBO 9.01
- SABS N/A
- 52 Week Low
- FEBO $0.93
- SABS $1.00
- 52 Week High
- FEBO $17.68
- SABS $5.01
- Technical
- Relative Strength Index (RSI)
- FEBO 52.81
- SABS 53.68
- Support Level
- FEBO $1.04
- SABS $1.30
- Resistance Level
- FEBO $1.22
- SABS $1.49
- Average True Range (ATR)
- FEBO 0.12
- SABS 0.13
- MACD
- FEBO 0.01
- SABS 0.04
- Stochastic Oscillator
- FEBO 62.07
- SABS 100.00
About FEBO Fenbo Holdings Limited
Fenbo Holdings Ltd is a company engaged in producing premium personal care electric appliances principally electrical hair styling products such as straighteners, curlers, trimmers, etc., and toy products to overseas markets. It manufactures and sells products such as Straightener, Mini Straightener, and Curling Iron.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.